161 related articles for article (PubMed ID: 16187088)
1. A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors.
Sun Z; Lethé B; Zhang Y; Russo V; Colau D; Stroobant V; Boon T; van der Bruggen P
Cancer Immunol Immunother; 2006 Jun; 55(6):644-52. PubMed ID: 16187088
[TBL] [Abstract][Full Text] [Related]
2. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.
Mandic M; Almunia C; Vicel S; Gillet D; Janjic B; Coval K; Maillere B; Kirkwood JM; Zarour HM
Cancer Res; 2003 Oct; 63(19):6506-15. PubMed ID: 14559844
[TBL] [Abstract][Full Text] [Related]
3. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.
Godelaine D; Carrasco J; Brasseur F; Neyns B; Thielemans K; Boon T; Van Pel A
Cancer Immunol Immunother; 2007 Jun; 56(6):753-9. PubMed ID: 17096150
[TBL] [Abstract][Full Text] [Related]
4. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
[TBL] [Abstract][Full Text] [Related]
5. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
[TBL] [Abstract][Full Text] [Related]
6. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C
Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308
[TBL] [Abstract][Full Text] [Related]
7. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules.
So T; Hanagiri T; Chapiro J; Colau D; Brasseur F; Yasumoto K; Boon T; Coulie PG
Cancer Immunol Immunother; 2007 Feb; 56(2):259-69. PubMed ID: 16758204
[TBL] [Abstract][Full Text] [Related]
8. Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28.
Han JF; Zhao TT; Liu HL; Lin ZH; Wang HM; Ruan ZH; Zou LY; Wu YZ
Cancer Immunol Immunother; 2006 Dec; 55(12):1575-83. PubMed ID: 16534571
[TBL] [Abstract][Full Text] [Related]
9. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames.
Wang RF; Johnston SL; Zeng G; Topalian SL; Schwartzentruber DJ; Rosenberg SA
J Immunol; 1998 Oct; 161(7):3598-606. PubMed ID: 9759882
[TBL] [Abstract][Full Text] [Related]
10. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.
Corbière V; Nicolay H; Russo V; Stroobant V; Brichard V; Boon T; van der Bruggen P
Tissue Antigens; 2004 May; 63(5):453-7. PubMed ID: 15104676
[TBL] [Abstract][Full Text] [Related]
11. Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber.
Slager EH; van der Minne CE; Goudsmit J; van Oers JM; Kostense S; Havenga MJ; Osanto S; Griffioen M
Cancer Gene Ther; 2004 Mar; 11(3):227-36. PubMed ID: 14726960
[TBL] [Abstract][Full Text] [Related]
12. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D
J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859
[TBL] [Abstract][Full Text] [Related]
13. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
[TBL] [Abstract][Full Text] [Related]
14. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.
Schultz ES; Lethé B; Cambiaso CL; Van Snick J; Chaux P; Corthals J; Heirman C; Thielemans K; Boon T; van der Bruggen P
Cancer Res; 2000 Nov; 60(22):6272-5. PubMed ID: 11103782
[TBL] [Abstract][Full Text] [Related]
15. A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells.
Ottaviani S; Colau D; van der Bruggen P; van der Bruggen P
Cancer Immunol Immunother; 2006 Jul; 55(7):867-72. PubMed ID: 16151806
[TBL] [Abstract][Full Text] [Related]
16. Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes.
De Plaen E; Lurquin C; Lethé B; van der Bruggen P; Brichard V; Renauld JC; Coulie P; Van Pel A; Boon T
Methods; 1997 Jun; 12(2):125-42. PubMed ID: 9184377
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells.
Stronen E; Abrahamsen IW; Gaudernack G; Wälchli S; Munthe E; Buus S; Johansen FE; Lund-Johansen F; Olweus J
Scand J Immunol; 2009 Apr; 69(4):319-28. PubMed ID: 19284496
[TBL] [Abstract][Full Text] [Related]
18. A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells.
Ottaviani S; Zhang Y; Boon T; van der Bruggen P
Cancer Immunol Immunother; 2005 Dec; 54(12):1214-20. PubMed ID: 16025263
[TBL] [Abstract][Full Text] [Related]
19. Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells.
Susumu S; Nagata Y; Ito S; Matsuo M; Valmori D; Yui K; Udono H; Kanematsu T
Cancer Sci; 2008 Jan; 99(1):107-12. PubMed ID: 17991294
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
